JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Abstract
Cytokines play a central role in the pathophysiology of autoimmune and inflammatory diseases. Several cytokines signal through the JAK-STAT pathway, which is now recognized as a major target to inhibit the effect of a wide array of cytokines. JAK inhibitors are increasingly used in the setting of inflammatory and autoimmune diseases. While the currently approved drugs are panJAK inhibitors, more selective small molecules are being developed and tested in various rheumatic disorders. In this extensive review, we present evidence- or hypothesis-based perspectives for these drugs in various rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, and autoinflammatory diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibition of HIF-α hydroxylation can be achieved using PHD inhibitors, including Roxadustat, which is approved in China and Europe for the treatment of renal anemia in CKD, and daprodustat, vadadustat, enarodustat and molidustat, which have been approved in Japan.
“As such, inhibition of HIF-α hydroxylation can be achieved using PHD inhibitors, such as Roxadustat, which is approved in China and Europe for the treatment of renal anemia in CKD, and other PHD inhibitors, daprodustat, vadadustat, enarodustat and molidustat, which have been approved in Japan.637–642”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [640]
The citation lists haven’t been fetched yet
References 199 · Cited by 264
- Authors
- Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P.
- Affiliations
- Hospices Civils de Lyon (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Inserm (FR)
- Corresponding author
- Jamilloux, Yvan
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 18
- Issue
- 11
- Pages
- 102390
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W2973019461
- Cited by
- 264
- References
- 199
- Citations by year
- 2026: 13 · 2025: 37 · 2024: 32 · 2023: 28 · 2022: 48 · 2021: 57 · 2020: 43 · 2019: 6
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Autoimmunity Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- JAK inhibitors, JAK/STAT signaling, cytokines, autoimmune disease, inflammatory diseases, rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, autoinflammatory disease
- MeSH terms
- Janus Kinase Inhibitors, Animals, Anti-Inflammatory Agents, Autoimmune Diseases, Humans, Rheumatic Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
